Episode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser Blood Cancer Talks

In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser. 
Here are the shownotes:
1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma: 
https://x.com/Rfonsi1/status/1206004966294294528?s=20
 
2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:
https://pubmed.ncbi.nlm.nih.gov/28655925/
 
3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):
https://pubmed.ncbi.nlm.nih.gov/33129376/
 
4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:
https://pubmed.ncbi.nlm.nih.gov/36779691/
 
5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):
https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(23)X0011-1?pageStart=0
 
6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:
https://pubmed.ncbi.nlm.nih.gov/34388020/
 
7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:
https://pubmed.ncbi.nlm.nih.gov/34470049/